WARRINGTON, Pa., Nov. 6, 2015 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology
company focused on developing aerosolized KL4 surfactant therapies
for respiratory diseases, will announce top-line results from its
AEROSURF® Phase 2a expansion clinical trial in premature
infants 29 – 34 gestational age with respiratory distress syndrome
(RDS) on Thursday, November 12, 2015
at approximately 7:00 a.m. EST.
Discovery Labs management will host a conference call and live
webcast, including a slide presentation, on Thursday, November 12, 2015 at 8:00 a.m. EST
to review and discuss the results of the trial. The live webcast
and archive of the conference call can be accessed at
http://discoverylabs.investorroom.com/events.
For "listen-only" participants and those who wish to take part
in the question and answer portion of the call, dial (888) 346-0767
(domestic) or (412) 902-4251 (international). After placing the
call, request to be joined into the Discovery Labs conference
call. A replay of the conference call will be accessible one
hour after completion through November 20,
2015 by dialing (877) 344-7529 (domestic) or (412) 317-0088
(international) and referencing conference ID number 10076116.
About Discovery Labs
Discovery Laboratories, Inc. is a
specialty biotechnology company focused on developing aerosolized
KL4 surfactant therapies for respiratory diseases.
Surfactants are produced naturally in the lung and are essential
for normal respiratory function and survival. If surfactant
deficiency or degradation occurs, the air sacs in the lungs can
collapse, resulting in severe respiratory diseases and
disorders. Discovery Labs' technology platform includes a
novel synthetic peptide-containing (KL4) surfactant, that is
structurally similar to pulmonary surfactant, and proprietary drug
delivery technologies being developed to enable efficient delivery
of aerosolized KL4 surfactant. Discovery Labs believes that
its proprietary technology platform makes it possible, for the
first time, to develop a significant pipeline of aerosolized
surfactant products to address a variety of respiratory diseases
for which there frequently are few or no approved therapies.
For more information, please visit the Company's website at
www.Discoverylabs.com.
Forward-Looking Statements
To the extent
that statements in this press release are not strictly historical,
all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
Examples of such risks and uncertainties are described in Discovery
Labs' filings with the Securities and Exchange Commission,
including the most recent reports on Forms 10-K, 10-Q and 8-K, and
any amendments thereto. Except as otherwise required by law,
Discovery Labs undertakes no obligation to update or revise any
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-to-announce-results-from-aerosurf-phase-2a-expansion-clinical-trial-300173773.html
SOURCE Discovery Laboratories, Inc.
